Bhupendra Khatri, MD
Neurology · Milwaukee, WINPI 1013982594
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,628,252 of the $2,453,680 with a category attached, or 66.4%. It is spread thinly across 28 manufacturers, the largest accounting for just 20.7%. Reporting peaked in 2019 at $832,630 and has fallen 73.5% since, to $220,335 in 2025. Among neurology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,631 payments — averaging $1504.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$508K
- AstraZeneca$444K
- EMD Serono, Inc.$283K
- Biogen$244K
- E.r. Squibb & Sons, L.L.C.$193K
- Genentech USA, Inc.$190K
- plus $592K from 22 others
Across 849 payments — averaging $5922.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.9M
- Genentech, Inc.$942K
- Biogen$614K
- UCB SA$440K
- Sanofi$396K
- AstraZeneca$145K
- plus $549K from 13 others
What the payments were for
- Consulting fees$548,51422%
- Speaking & faculty fees$1,628,25266%
- Travel & lodging$247,33910%
- Food & beverage$29,4971%
- Education$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 283 | $508,127 |
| AstraZeneca | 285 | $443,634 |
| EMD Serono, Inc. | 208 | $283,037 |
| Biogen | 183 | $243,944 |
| E.r. Squibb & Sons, L.L.C. | 115 | $193,151 |
| Genentech USA, Inc. | 122 | $190,132 |
| Bristol Myers Squibb | 140 | $149,752 |
| Sanofi-aventis U.S. LLC | 15 | $127,811 |
| TG Therapeutics, Inc. | 89 | $123,240 |
| Amgen | 47 | $61,185 |
| Novartis | 58 | $56,885 |
| UCB, Inc. | 36 | $36,225 |
| Terumo BCT, Inc. | 5 | $14,792 |
| Johnson & Johnson | 10 | $14,048 |
| Argenx US, Inc. | 5 | $3,797 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,360 |
| ANI Pharmaceuticals, Inc. | 1 | $1,275 |
| Grifols Shared Services North America, Inc. | 1 | $350 |
| Greenwich Biosciences, Inc. | 1 | $238 |
| AbbVie | 11 | $183 |
| Kyowa Kirin, Inc. | 3 | $180 |
| Genentech, Inc. | 1 | $105 |
| Teva Pharmaceuticals USA, Inc. | 3 | $57 |
| Lundbeck LLC | 2 | $49 |
| Octapharma USA, Inc. | 1 | $38 |
| Eisai Inc. | 2 | $38 |
| Banner Life Sciences, LLC | 2 | $32 |
| Acorda Therapeutics, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPOSIA$271,671
- Mavenclad$244,099
- LEMTRADA$237,135
- ULTOMIRIS$201,115
- AUBAGIO$190,842
- OCREVUS$182,052
- BRIUMVI$117,329
- SOLIRIS$117,266
- TYSABRI$117,014
- NO PRODUCT DISCUSSED$94,252
- UPLIZNA$60,522
- Ozanimod$56,407
- TECFIDERA$45,658
- Vumerity$34,714
- Rystiggo$18,245
- Ocrevus Zunovo$15,310
- GILENYA$13,942
- Zilbrysq$13,129
- MAYZENT$11,700
- Spectra Optia Apheresis System$10,723
How this compares
$2,453,680 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZeposiaOzanimod Hydrochloride | 15 | $132,036 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $89,685 |
| Teriflunomide | 14 | $31,601 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $9,840 |
| Dalfampridine ErDalfampridine | 41 | $7,312 |
| Baclofen | 21 | $703 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 19 | $360 |
| Pregabalin | 19 | $319 |
| Primidone | 14 | $278 |
| Gabapentin | 35 | $274 |
| Prednisone | 11 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Zeposia | $193,151 | $132,03615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 neurology providers in Wisconsin.
Other neurology in Milwaukee
- Ahmed ObeidatMilwaukee$1.9M
- Staley BrodMilwaukee$1M
- Sam HooshmandMilwaukee$229K
- Fallon SchloemerMilwaukee$48K
- Thulasirman RavichandranMilwaukee$47K
- Julia CollinsMilwaukee$21K
- Ryan BrennanMilwaukee$20K
- Elise JohnsonMilwaukee$11K
- Janel SchneiderMilwaukee$9K
- Teresa LeeMilwaukee$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.